Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 643 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR One Million Masks Donated! But GreaterGood Will Continue to Help Where... October 5, 2020 What to Know About Treatment Options Before and After Surgery for... November 7, 2023 PET Positivity After Two Cycles of ABVD Is Associated with a... November 22, 2023 Worse Survival Observed Among Patients Diagnosed with Cancer During the First... February 16, 2026 Load more HOT NEWS New Device Could “Hear” Stiffening of Extracellular Matrix to Determine Where... News digest – sponge on a string, junk food watershed, prostate... Longest Follow-Up of CAR T-Cell Therapy in Mantle Cell Lymphoma Points... Study Identifies Potential Drug Target to Prevent Some Liver Cancers
